Kiadis banks $36M in a Euro IPO to fund its stem cell R&D – FierceBiotech
|
Kiadis banks $36M in a Euro IPO to fund its stem cell R&D
FierceBiotech With its newfound funds, Kiadis plans to push forward in Phase II development with ATIR101, a stem cell therapy for aggressive blood cancers, including acute lymphoblastic leukemia (AML). The treatment is in the midst of an open-label Phase II trial to … |
